Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment

Recruiting Observational Study
Oral Neoplasm
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
15 – 90
Sex
Any
Study type
Observational
Participants needed
500 (estimated)
Sponsor
Proteocyte Diagnostics Inc. · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The purpose of this observational study is to evaluate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of progression to cancer of clinically suspicious oral lesions.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Any clinically suspicious lesion biopsied to rule-out oral epithelial dysplasia/oral squamous cell carcinoma Exclusion Criteria: * Biopsied lesion with or without dysplasia concomitant with oral squamous cell carcinoma at initial biopsy
Contacts

Jason Hwang, PhD

(647) 255-1370

jhwang@proteocyte.com

CONTACT

Mark Darling, MSc, MChD

(519) 661-2111

mark.darling@schulich.uwo.ca

CONTACT